ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer

ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer

2024.01.31
 Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered an oral presentation at the 17th International Liver Cancer Association Annual Meeting (ILCA 2023) (Abstract No.: O-04). The study aimed to assess the dynamic changes in ctDNA levels in hepatocellular carcinoma (HCC) patients across different tumor stages and during anti-cancer treatments. The findings highlighted the significant clinical relevance of monitoring ctDNA levels for HCC patients. Dr. Claudia Campani was honored with the "Young Investigator" award by the ILCA conference.
Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma

Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma

2024.01.31
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1 monotherapy 1.0, combined molecular targeted drug application 2.0, and further combined local treatment 3.0. With ongoing clinical research, the effectiveness of HCC immunotherapy has greatly improved. So, what will the era of HCC immunotherapy 4.0 look like? What challenges will we face next? At the recently concluded 17th International Liver Cancer Association (ILCA) Annual Meeting, Hepatology Digest had the honor of conducting an in-depth interview with Dr. Tim Greten from the National Institutes of Health and the National Cancer Institute's Cancer Research Center.
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

2024.01.31
 Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer, monitor treatment effects in real-time, and prevent metastasis. Liquid biopsy technology has attracted attention in recent years as a new detection method. It is non-invasive, sensitive, and dynamic, showing promise in early tumor diagnosis, personalized medication guidance, and treatment monitoring. At the 17th International Liver Cancer Association Annual Meeting (ILCA 2023), Dr. Issei Saeki from School of Medicine of Yamaguchi University,Japan, reported a study (Abstract number: O-11) that assessed the clinical application value of liquid biopsy technology based on the methylated SEPT9 test for early diagnosis of non-viral hepatitis-related hepatocellular carcinoma (N-HCC).
ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

2024.01.31
 After the HIV virus enters the human body, it first destroys the immune system, leading to a rapid decline in immunity. Consequently, the body becomes more susceptible to various infections and complications, the most common of which are infections in different systems and malignant tumors. As the life expectancy of people living with HIV (PLWH) increases, cases of coexisting malignant tumors are also on the rise. From September 7-9, 2023, the seventeenth International Liver Cancer Association (ILCA) annual meeting (ILCA 2023) was grandly held in Amsterdam, the capital of the Netherlands. At this conference, Dr. Eleonora Alimenti from the University of Pavia, Italy, orally presented the clinical features, treatment status, and clinical outcomes of PLWH coexisting with HCC at Lombardy's Third Hospital in Italy (Conference Abstract: O-07), drawing significant attention.
Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

2024.01.31
 Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the epithelium of secondary bile ducts and their branches, accounting for 10%-15% of primary malignant tumors in the liver. In recent years, the incidence of ICC has been rising significantly, garnering increasing clinical attention. While ICC and hepatocellular carcinoma (HCC) both belong to primary liver cancers, they have distinct biological characteristics. The complex disease characteristics and prognosis pose significant challenges for ICC's clinical treatment. From September 7-9, 2023, the 17th annual meeting of the International Liver Cancer Association (ILCA) was grandly held in Amsterdam, Netherlands. At the conference, Dr. Qiang Gao from Zhongshan Hospital, Fudan University, China, shared recent advancements in the study of tumor-immune interactions in ICC. This article compiles an in-depth interview with Dr. Gao for our readers.
Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

2024.01.31
Welcome to a special feature by Oncology Frontier, where we bridge the gap between continents in the realm of medical innovation. Today, we're honored to host Marie-Pier St-Laurent from the University of British Columbia. As part of our exclusive Specialist Interview series, Marie-Pier will be sharing valuable insights from her recent abstract presented at ASCO GU. Stay tuned as we delve into groundbreaking research that's shaping the future of oncological care. Visit us at www.ioncol.com for more thought-provoking content